The shares of United Therapeutics Corporation (NASDAQ:UTHR) traded with a loss of -1.34 points or -1.2% in the most recent session. The shares last traded at $110.01. As per the trading info, the shares saw $5.41 million in upticks and lost $4.09 million in downticks, resulting in a net money flow of $1.32 million. The up/down ratio for the day was measured at 1.32. For the week, the shares had posted -5.42%.From the block trade data available, the total upticks were valued at $1.81 million and the total downticks were valued at $0 million, thereby putting the up/down ratio at 0. The net money flow for the block transaction was $1.81 million.
Currently the company Insiders own 8.5% of United Therapeutics Corporation shares according to the proxy statements. On the companys insider trading activities, The director, of United Therapeutics Corp, Dwek Raymond had unloaded 3,000 shares at $166.28 per share in a transaction on August 6, 2015. The total value of transaction was $498,840. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
United Therapeutics Corporation (NASDAQ:UTHR) stock ended Monday session in the red zone in a volatile trading. The stock closed down 1.29 points or 1.16% at $110.06 with 564,568 shares getting traded. Post opening the session at $111.06, the shares hit an intraday low of $109.4001 and an intraday high of $112.75 and the price was in this range throughout the day. The company has a market cap of $4,911 million and the number of outstanding shares have been calculated to be 44,621,988 shares. The 52-week high of United Therapeutics Corporation (NASDAQ:UTHR) is $190.13 and the 52-week low is $102.5.
Many analysts have stated their opinion on the company shares. Argus Research downgrades its rating on United Therapeutics Corporation (NASDAQ:UTHR). Analysts at the Argus Research have a current rating of Hold on the shares. The shares were previously rated Buy. The rating by the firm was issued on May 24, 2016.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.